Kantarjian H M, Alexanian R, Koller C A, Kurzrock R, Keating M J
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Blood. 1990 May 15;75(10):1928-31.
Fludarabine, a fluorinated analogue of adenine, was given to 11 patients with macroglobulinemic lymphoma, all but one having failed prior standard chemotherapy. Five patients (45%) responded with more than a 50% reduction of immunoglobulin M (IgM) tumor mass for a projected median duration of longer than 1 year. The onset of remission was usually slow, with a median tumor halving time of 5.2 months in responding patients, emphasizing the importance of repeated courses of treatment. Fludarabine is an important new agent effective against macroglobulinemic lymphoma, and should be evaluated further in combination with other active modalities.
氟达拉滨是腺嘌呤的一种氟化类似物，被给予11例巨球蛋白血症淋巴瘤患者，除1例之外，其余患者先前的标准化疗均告失败。5例患者（45%）出现反应，免疫球蛋白M（IgM）肿瘤量减少超过50%，预计中位持续时间超过1年。缓解通常起效缓慢，有反应的患者肿瘤体积减半的中位时间为5.2个月，这凸显了重复疗程治疗的重要性。氟达拉滨是一种有效对抗巨球蛋白血症淋巴瘤的重要新药，应进一步与其他有效治疗方式联合进行评估。
